Eye imaging to predict worsening diabetic retinopathy in people with type 2 diabetes
Studies whether eye changes predict worsening diabetic retinopathy and heart problems in type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Analysis of DR Progression to Identify Risks and Need for Treatment
Key facts
- Where
- Portugal, PortugalSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 35 and 90 years old?
Source: NCT07417410, who can take part
Where in Portugal
- AIBILI-Clinical Trial CentrePortugal, PortugalTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Association for Innovation and Biomedical Research on Light and Image
- Trial code
- NCT07417410
- Record updated
- 2 March 2026
- Original description
The goal of this observational study is to understand whether vascular and structural changes in the eyes caused by diabetes can help predict which people are more likely to experience worsening diabetic retinopathy (a diabetes-related eye disease) and how these eye changes are related to cardiovascular complications.Read full original descriptionShow less
Analysis of DR Progression to Identify Risks and Need for Treatment
The goal of this observational study is to understand whether vascular and structural changes in the eyes caused by diabetes can help predict which people are more likely to experience worsening diabetic retinopathy (a diabetes-related eye disease) and how these eye changes are related to cardiovascular complications.
The study will include about 1,000 people with type 2 diabetes, aged 35 to 90 years, and will take place over twelve months. It may also include a retrospective component, where existing medical and imaging data collected from previous visits (within the last 1 to 5 years) will be analyzed.
The main questions it aims to answer are:
* Can eye vessel and tissue changes, observed through modern imaging techniques and clinical data, help better describe and predict which cases of diabetic retinopathy will become more severe? * Can these same eye changes help predict the presence and risk of cardiovascular problems-such as heart disease or stroke-in people living with type 2 diabetes?
Inclusion: Diagnosed with type 2 diabetes according to the 1985 WHO criteria; Age between 35 and 90 years; Retrospective visit or referenced patients. For the retrospective visit, a documented follow-up of 1-5 years is required, with at least one clinical visit. For the referenced patients, it is required that they have either diabetic retinopathy at the baseline visit, the presence of at least one cardiovascular risk factor at the baseline visit, or cardiovascular complications at the baseline visit; Signed informed consent.
Exclusion: Previous laser photocoagulation or intravitreal injections (consider if corticosteroids were administered); Any ocular surgery within the previous 3 months; Renal Replacement Therapy (Hemodialysis, Peritoneal Dialysis); Severe systemic illness, subject to investigator's judgment; Presence of clinically significant macular edema (CSME) with vision loss or requiring immediate treatment; Proliferative diabetic retinopathy.